Intravaginal and in vitro temperature changes with tampons of differing composition and absorbency

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 92, Issue 2, 2010, Pages 535-541

  Hill, Donna R ^a   Davis, Catherine C ^a   Osborn III, Thomas W ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Biological fluid; Blood material interaction; Clinical; Sensor; Women's health

Indexed keywords

BIOLOGICAL FLUIDS; BLOOD-MATERIAL INTERACTION; BLOOD-MATERIAL INTERACTIONS; CARBOXYMETHYL CELLULOSE; CLASS II; CONTROLLED CONDITIONS; EXOTHERMIC EVENTS; FLUID ABSORPTION; FLUID SATURATIONS; HOLLOW GLASS; IN-VITRO; MEDICAL DEVICES; SUPINE POSITION; TEMPERATURE CHANGES; TEMPERATURE EFFECTS; TEMPERATURE PROFILES; THERMOCOUPLE SENSORS; WATER BATHS; WOMEN'S HEALTH;

ABSORPTION; BIOLOGICAL MATERIALS; BLOOD; CELLULOSE; SENSORS; THERMOCOUPLES;

FLUIDS;

CARBOXYMETHYLCELLULOSE;

ABSORPTION; ARTICLE; BACTERIAL COLONIZATION; CONDOM; COTTON; HUMAN; IN VITRO STUDY; MENSTRUATION; ROOM TEMPERATURE; SENSOR; SPIKE; SUPINE POSITION; TAMPON; TEMPERATURE SENSITIVITY; VAGINA;

ABSORPTION; BIOSENSING TECHNIQUES; BODY TEMPERATURE; CARBON DIOXIDE; CARBOXYMETHYLCELLULOSE; CELLULOSE; COTTON FIBER; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MENSTRUAL HYGIENE PRODUCTS; MENSTRUATION; OXYGEN; TEMPERATURE; YOUNG ADULT;

ABSORPTION; BACTERIAL COUNT; BLOOD; CARBOXYMETHYL CELLULOSE; CELLULOSE; EXOTHERMIC REACTIONS; FLUID; MEDICAL SURGICAL SUPPLIES; PROTOTYPES; SENSORS; TAMPONS; TEMPERATURE; THERMOCOUPLES;

EID: 74749107887     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31550     Document Type: Article

References (38)

1. Gad SC. Road Map to Test Selections. Safety Evaluation of Medical Devices, 2nd ed. New York: Marcel Dekker; 2002. p 75.
2. United States Food and Drug Administration, Department of Health and Human Services. [homepage on the Internet]. Washington, DC: Title 21 Food and Drugs, Subchapter H Medical Devices, Subpart F Obstetrical and Gynecological Therapeutic Devices §884.5460 and §884.5670; [updated as of 2008 April 1; cited 9 April 2009]. Available at: http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart5884.
3. Friedman N. Invented by a doctor; a medical and social history of tampons. In: Wolner R, editor. Everything You Must Know About Tampons. New York: Berkley Publishing Group; 1981.
4. Czerwinski BS. Variation in feminine hygiene practices as a function of age. J Obstet Gynecol Neonatal Nurs 2000;29:625-633.
5. Finkelstein JW, von Eye A. Sanitary product use by white, black, and Mexican-American women. Public Health Rep 1990;105:491-496.
6. Omar HA, Aggarwal S, Perkins KC. Tampon use in young women. J Pediatr Adolesc Gynecol 1998;11:143-146.
7. Absorbent Hygiene Product Manufacturers Association (AHPMA) [homepage on the Internet]. Surrey, England: Tampons Working Group of the European Disposables and Nonwovens Association (EDANA) [cited 23 March 2009]. Tampons for menstrual hygiene; modern products with ancient roots, pp 1-6. Available at:http://www.ahpma.co.uk/docs/Tampon%20Dossier%202006-07-%202.pdf.
8. United States Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health. [homepage on the Internet]. Washington, DC: Guidance for Industry and FDA Staff: Menstrual Tampons and Pads: Information for Premarket noti.cation Submissions (510(k)s); [issued on 2005 July 27; cited 23 March 2009]. Available at:http://www.fda.gov/ cdrh/ode/guidance/166.pdf.
9. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, Fraser DW. Toxic-shock syndrome in menstruating women: Association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980;303:1436-1442.
10. Schwartz B, Gaventa S, Broome CV, Reingold AL, Hightower AW, Perlman JA, Wolf PH. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: Report of a case-control study. Rev Infect Dis 1989;11 (Suppl 1): S43-S48; discussion S48-S49.
11. Kass EH, Kendrick MI, Tsai YC, Parsonnet J. Interaction of magnesium ion, oxygen tension, and temperature in the production of toxic-shock-syndrome toxin-1 by Staphylococcus aureus. J Infect Dis 1987;155:812-815.
12. Schlievert PM, Blomster DA. Production of staphylococcal pyrogenic exotoxin type C: Influence of physical and chemical factors. J Infect Dis 1983;147:236-242.
13. Wagner G, Ottesen B Vaginal physiology during menstruation. Ann Intern Med 1982;96(Part 2):921-923.
14. Hill DR, Brunner ME, Schmitz DC, Davis CC, Flood JA, Schlievert PM, Wang-Weigand SZ, Osborn TW. In vivo assessment of human vaginal oxygen and carbon dioxide levels during and post menses. J Appl Physiol 2005;99:1582-1591.
15. Chvapil M, Holusa R. Experimental experiences with the collagen sponge as hemostaticum and tampon. J Biomed Mater Res 1968;2:245-264.
16. Molnar GW Investigation of hot flashes by ambulatory monitoring. Am J Physiol 1979;237:R306-R310.
17. Calvert J, Duck F, Clift S, Azaime H. Surface heating by transvaginal transducers. Ultrasound Obstet Gynecol 2007;29:427-432.
18. Lee Wong AC, Downs SA. Investigation by improved syringe method of effect of tampons on production in vitro of toxic shock syndrome toxin 1 by Staphylococcus aureus. J Clin Microbiol 1989;27:2482-2487.
19. Kaczmarzyk LM, Hlaban JJ, Bernardin LJ; Kimberly-Clark Corporation, assignee. Compressed catamenial tampons with improved capabilities for absorbing menstrual fluids. US patent 4,044,766; 1977.
20. United States Food and Drug Administration, Department of Health and Human Services. [homepage on the Internet]. Washington, DC: Title 21 Food and Drugs, Subchapter H Medical Devices, Subpart H Special Requirements for Specific Devices, §801.430 User labeling for menstrual tampons; [updated as of 2008 April 1; cited 9 April 2009]. Available at: http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr5801.430.
21. Szaflarski NL. Emerging technology in critical care: Continuous intra-arterial blood gas monitoring. Am J Crit Care 1996;5:55-65.
22. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet 1978;2:1116-1118.
23. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: Epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980;303:1429-1435.
24. Osterholm MT, Davis JP, Gibson RW, Mandel JS, Wintermeyer LA, Helms CM, Forfang JC, Rondeau J, Vergeront JM. Tri-state toxic-shock syndrome study. I. Epidemiologic findings. J Infect Dis 1982;145:431-440.
25. Nelson E, Jordan M. Sensitive export: Seeking new markets for tampons, P&G faces cultural barriers. Wall Street J December 8, 2000; Section A; Page 1, Column 6.
26. Magrid MO, Geiger J. The intravaginal tampon in menstrual hygiene: A clinical study. Med Rec 1942;155:316-318.
27. Shehin SE, Jones MB, Hochwalt AE, Sarbaugh FC, Nunn S. Clinical safety-in-use study of a new tampon design. Infect Dis Obstet Gynecol 2003;11:89-99.
28. Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 2004;42:2875-2876.
29. Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, Onderdonk AB. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 2005;43:4628-4634.
30. Vergeront JM, Stolz SJ, Crass BA, Nelson DB, Davis JP, Bergdoll MS. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: Implications for toxic-shock syndrome. J Infect Dis 1983;148:692-698.
31. Kansal R, Davis C, Hansmann M, Seymour J, Parsonnet J, Modern P, Gilbert S, Kotb M. Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome. J Clin Immunol 2007;27:327-338.
32. Wong ACL. Factors Affecting Growth of Staphylococcus aureus and Production of Toxic Shock Syndrome Toxin-1 [Ph.D.]. Madison, WI: University of Wisconsin; 1987.
33. Ledger WJ, Witkin SS. Microbiology of the vagina. In: Ledger WJ, Witkin SS, editors. Vulvovaginal Infections. London, England: Manson Publishing; 2007. p 11.
34. Wagner G, Bohr L, Wagner P, Petersen LN. Tampon-induced changes in vaginal oxygen and carbon dioxide tensions. Am J Obstet Gynecol 1984;148:147-150.
35. Reiser RF, Hinzman SJ, Bergdoll MS. Production of toxic shock syndrome toxin 1 by Staphylococcus aureus restricted to endogenous air in tampons. J Clin Microbiol 1987;25:1450-1452.
36. Berkley SF, Hightower AW, Broome CV, Reingold AL. The relationship of tampon characteristics to menstrual toxic shock syndrome. JAMA 1987;258:917-920.
37. Lanes SF, Rothman KJ. Tampon absorbency, composition and oxygen content and risk of toxic shock syndrome. J Clin Epidemiol 1990;43:1379-1385.
38. Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: Surveillance update, 1979-1996. Emerg Infect Dis 1999;5:807-810.